NASDAQ:EPZM - Epizyme Stock Price, Price Target & More

$15.80 -0.05 (-0.32 %)
(As of 04/23/2018 11:42 AM ET)
Previous Close$15.85
Today's Range$15.70 - $16.35
52-Week Range$9.30 - $21.40
Volume48,781 shs
Average Volume428,512 shs
Market Capitalization$1.10 billion
P/E Ratio-7.27
Dividend YieldN/A
Beta1.95

About Epizyme (NASDAQ:EPZM)

Epizyme logoEpizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL. It has collaboration agreements with Celgene Corporation, Genentech Inc., and Glaxo Group Limited, as well as with Roche Molecular Systems, Inc., Eisai Co. Ltd., and Lymphoma Study Association. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM News and Ratings via Email

Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EPZM
CUSIPN/A
Phone617-229-5872

Debt

Debt-to-Equity RatioN/A
Current Ratio11.59%
Quick Ratio11.59%

Price-To-Earnings

Trailing P/E Ratio-7.27
Forward P/E Ratio-6.64
P/E GrowthN/A

Sales & Book Value

Annual Sales$10 million
Price / Sales109.78
Cash FlowN/A
Price / CashN/A
Book Value$3.40 per share
Price / Book4.65

Profitability

EPS (Most Recent Fiscal Year)($2.18)
Net Income$-134,300,000.00
Net MarginsN/A
Return on Equity-64.88%
Return on Assets-51.70%

Miscellaneous

Employees131
Outstanding Shares69,480,000

How to Become a New Pot Stock Millionaire

Epizyme (NASDAQ:EPZM) Frequently Asked Questions

What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

How were Epizyme's earnings last quarter?

Epizyme (NASDAQ:EPZM) announced its quarterly earnings results on Tuesday, March, 13th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks' consensus estimate of ($0.57) by $0.05. The firm's quarterly revenue was down 100.0% compared to the same quarter last year. View Epizyme's Earnings History.

When is Epizyme's next earnings date?

Epizyme is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Epizyme.

What price target have analysts set for EPZM?

12 Wall Street analysts have issued 12 month price objectives for Epizyme's stock. Their predictions range from $16.00 to $27.00. On average, they anticipate Epizyme's stock price to reach $23.6364 in the next twelve months. View Analyst Ratings for Epizyme.

What are Wall Street analysts saying about Epizyme stock?

Here are some recent quotes from research analysts about Epizyme stock:
  • 1. According to Zacks Investment Research, "Epizyme reported narrower than expected loss in the fourth quarter of 2017. Epizyme's efforts on developing its lead candidate, tazemetostat, for a number of hematological malignancies and genetically defined solid tumors are impressive. During the fourth quarter of 2017, the company had a productive interaction with the FDA to design the registration strategy for tazemetostat for epithelioid sarcomaand follicular lymphoma (FL) and identified a path to submit for accelerated approval for both the indications. The company plans to file a first new drug application of tazemetostat for epithelioid sarcoma in fourth quarter of 2018 and second NDA for FL in 2019. A potential approval for the candidate will be a significant boost for the company. So far this year, Epizyme’s share price has also outperformed the industry. However, the company is highly dependent on its collaboration partners for top-line growth with no approved product." (3/16/2018)
  • 2. Cann analysts commented, "Epizyme presented two posters at the American Society of Hematology Meeting on December 10-11, 2017. These included a biomarker study in non-Hodgkin’s lymphoma (NHL) and preliminary response data from the diffuse large B cell lymphoma (DLBCL) cohort from the ongoing phase II study of tazemetostat in NHL. The data presented is very supportive of our outlook." (12/12/2017)

Who are some of Epizyme's key competitors?

Who are Epizyme's key executives?

Epizyme's management team includes the folowing people:
  • Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 50)
  • Dr. H. Robert Horvitz Ph.D., M.D., Co-Founder and Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang Ph.D., Scientific Co-Founder and Member of The Scientific Advisory Board
  • Mr. Matthew E. Ros, Chief Operating Officer (Age 51)
  • Dr. Michael Boretti Ph.D., VP of Bus. Devel.

Has Epizyme been receiving favorable news coverage?

Media coverage about EPZM stock has been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Epizyme earned a media sentiment score of 0.00 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 45.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Epizyme?

Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $15.80.

How big of a company is Epizyme?

Epizyme has a market capitalization of $1.10 billion and generates $10 million in revenue each year. The biopharmaceutical company earns $-134,300,000.00 in net income (profit) each year or ($2.18) on an earnings per share basis. Epizyme employs 131 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected]


MarketBeat Community Rating for Epizyme (EPZM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  304 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  494
MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Epizyme (NASDAQ:EPZM) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Epizyme in the last 12 months. Their average twelve-month price target is $23.6364, suggesting that the stock has a possible upside of 49.60%. The high price target for EPZM is $27.00 and the low price target for EPZM is $16.00. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.922.922.913.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.6364$23.6364$22.6667$24.25
Price Target Upside: 49.60% upside24.08% upside81.33% upside25.97% upside

Epizyme (NASDAQ:EPZM) Consensus Price Target History

Price Target History for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2018WedbushReiterated RatingOutperform$26.00 -> $25.00HighView Rating Details
3/14/2018Leerink SwannBoost Price TargetOutperform -> Outperform$22.00 -> $24.00HighView Rating Details
3/14/2018SunTrust BanksReiterated RatingBuy$27.00HighView Rating Details
2/1/2018Roth CapitalInitiated CoverageBuy$24.00MediumView Rating Details
1/24/2018Jefferies GroupReiterated RatingBuy -> Buy$25.00LowView Rating Details
1/10/2018Morgan StanleyInitiated CoverageOverweight -> Overweight$20.00HighView Rating Details
12/12/2017OppenheimerSet Price TargetBuy$26.00MediumView Rating Details
12/12/2017CannReiterated RatingBuy$26.00MediumView Rating Details
11/2/2017HC WainwrightReiterated RatingBuy$25.00N/AView Rating Details
11/2/2017Royal Bank of CanadaDowngradeOutperform -> Sector Perform$20.00 -> $16.00N/AView Rating Details
6/16/2017CitigroupBoost Price TargetBuy$20.00 -> $22.00LowView Rating Details
6/7/2017CowenReiterated RatingBuyHighView Rating Details
4/13/2017CIBCReiterated RatingOutperform -> OutperformLowView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
6/20/2016MizuhoReiterated RatingBuy$18.00N/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

Epizyme (NASDAQ:EPZM) Earnings History and Estimates Chart

Earnings by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) Earnings Estimates

2018 EPS Consensus Estimate: ($2.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($0.56)($0.52)($0.54)
Q2 20185($0.68)($0.53)($0.59)
Q3 20185($0.80)($0.51)($0.63)
Q4 20185($0.97)($0.46)($0.67)

Epizyme (NASDAQ EPZM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.55)N/AView Earnings Details
3/13/2018Q4 2017($0.57)($0.52)$0.11 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.65)($0.63)$0.19 millionViewN/AView Earnings Details
8/4/2017Q2 2017($0.56)($0.48)$3.95 million$10.00 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.63)($0.56)$0.49 millionViewN/AView Earnings Details
3/9/2017Q4 2016($0.65)($0.60)$0.61 million$0.48 millionViewListenView Earnings Details
11/3/2016Q3($0.60)($0.42)$0.57 million$6.58 millionViewListenView Earnings Details
8/8/2016Q2($0.52)($0.49)$0.61 million$0.47 millionViewListenView Earnings Details
5/9/2016Q1($0.53)($0.41)$0.58 million$0.47 millionViewListenView Earnings Details
3/9/2016Q415($0.65)($0.53)$0.66 million$0.56 millionViewListenView Earnings Details
11/9/2015Q315($0.59)($0.56)$8.75 million$0.36 millionViewListenView Earnings Details
8/6/2015Q215($0.70)($0.63)$2.23 million$0.74 millionViewListenView Earnings Details
4/28/2015Q115($0.99)($1.75)$6.48 million$0.91 millionViewN/AView Earnings Details
3/12/2015Q414($0.54)($0.44)$10.10 million$10.35 millionViewListenView Earnings Details
11/6/2014Q314($0.54)($0.58)$7.00 million$8.20 millionViewN/AView Earnings Details
8/13/2014Q214($0.46)($0.40)$7.59 million$9.50 millionViewN/AView Earnings Details
5/13/2014Q114($0.48)($0.22)$7.67 million$13.39 millionViewN/AView Earnings Details
2/27/2014Q413($0.22)$0.52$9.00 million$36.32 millionViewN/AView Earnings Details
10/22/2013Q3 2013($0.36)($0.34)$8.07 million$8.44 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.26)($0.25)$11.27 million$14.84 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Epizyme (NASDAQ:EPZM) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Epizyme (NASDAQ EPZM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.50%
Institutional Ownership Percentage: 85.77%
Insider Trading History for Epizyme (NASDAQ:EPZM)
Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ EPZM) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2018Matthew RosCOOSell72,264$16.63$1,201,750.3274,867View SEC Filing  
10/24/2017Peter Tai-Ching HoInsiderSell15,000$16.44$246,600.0023,123View SEC Filing  
9/25/2017Peter Tai-Ching HoInsiderSell15,000$16.81$252,150.0023,123View SEC Filing  
9/18/2017David M MottDirectorBuy200,000$15.25$3,050,000.006,000View SEC Filing  
8/24/2017Peter Tai-Ching HoInsiderSell15,000$15.68$235,200.0022,228View SEC Filing  
7/24/2017Peter Tai-Ching HoInsiderSell15,000$13.44$201,600.0022,228View SEC Filing  
6/30/2017Andrew E SingerCFOSell3,024$15.50$46,872.0040,529View SEC Filing  
6/26/2017Peter Tai-Ching HoInsiderSell15,000$14.87$223,050.0022,228View SEC Filing  
6/6/2017Robert A CopelandInsiderSell2,500$13.45$33,625.0034,038View SEC Filing  
5/25/2017Peter Tai-Ching HoInsiderSell15,000$16.11$241,650.0022,228View SEC Filing  
5/2/2017Robert A CopelandInsiderSell5,000$17.44$87,200.0036,538View SEC Filing  
4/4/2017Robert A CopelandInsiderSell5,000$16.36$81,800.0033,538View SEC Filing  
3/31/2017Andrew E SingerCFOSell2,013$17.09$34,402.1736,175View SEC Filing  
1/9/2017Andrew E SingerCFOSell1,013$12.04$12,196.5233,506View SEC Filing  
12/9/2016Andrew E SingerCFOSell1,013$11.03$11,173.3932,060View SEC Filing  
11/9/2016Andrew E SingerCFOSell1,013$10.40$10,535.2030,613View SEC Filing  
10/10/2016Andrew E SingerCFOSell1,013$9.72$9,846.3629,167View SEC Filing  
9/9/2016Andrew E SingerCFOSell1,013$7.55$7,648.1527,721View SEC Filing  
8/9/2016Andrew E SingerCFOSell1,013$9.05$9,167.6526,274View SEC Filing  
8/1/2016Robert A CopelandInsiderSell4,000$10.37$41,480.0035,538View SEC Filing  
7/11/2016Andrew E SingerCFOSell1,013$10.36$10,494.6824,828View SEC Filing  
7/5/2016Robert A CopelandInsiderSell4,000$10.03$40,120.004,000View SEC Filing  
6/9/2016Andrew E SingerCFOSell1,013$12.49$12,652.3723,382View SEC Filing  
4/12/2016Andrew E SingerCFOSell1,013$12.42$12,581.4620,489View SEC Filing  
3/9/2016Andrew E SingerCFOSell1,006$9.33$9,385.9819,036View SEC Filing  
2/29/2016Peter Tai-Ching HoInsiderBuy636$7.47$4,750.92View SEC Filing  
2/10/2016Andrew E. SingerCFOSell12,158$9.54$115,987.3217,354View SEC Filing  
1/12/2016Bay City Capital Fund V Co-InvMajor ShareholderBuy555,555$9.00$4,999,995.00View SEC Filing  
1/12/2016David M MottDirectorBuy1,111,111$9.00$9,999,999.00View SEC Filing  
1/4/2016Robert A. CopelandinsiderSell4,185$15.58$65,202.30View SEC Filing  
12/30/2015Robert J. GouldDirectorSell32,108$18.01$578,265.08View SEC Filing  
12/9/2015Peter Tai-Ching HoInsiderBuy1,000$14.69$14,690.00View SEC Filing  
12/7/2015Robert A. CopelandinsiderSell4,185$13.82$57,836.70View SEC Filing  
11/9/2015Robert A. CopelandinsiderSell4,185$16.26$68,048.10View SEC Filing  
10/5/2015Robert A. CopelandinsiderSell4,185$14.43$60,389.55View SEC Filing  
9/8/2015Robert A. CopelandinsiderSell4,185$19.58$81,942.30View SEC Filing  
9/8/2015Robert J. GouldCEOSell60,000$19.86$1,191,600.00View SEC Filing  
7/6/2015Robert A CopelandInsiderSell8,371$22.86$191,361.06View SEC Filing  
7/6/2015Robert J GouldCEOSell60,000$23.22$1,393,200.00View SEC Filing  
5/5/2015Peter Tai-Ching HoInsiderBuy800$16.36$13,088.00View SEC Filing  
12/2/2014Peter Tai-Ching HoInsiderBuy1,000$21.17$21,170.00View SEC Filing  
11/17/2014Robert A CopelandEVPSell20,000$22.68$453,600.00View SEC Filing  
11/3/2014Robert A CopelandEVPSell20,000$25.47$509,400.00View SEC Filing  
11/3/2014Robert J GouldCEOSell30,000$24.95$748,500.00View SEC Filing  
10/7/2014Robert A CopelandEVPSell20,000$26.90$538,000.00View SEC Filing  
10/1/2014Robert J GouldCEOSell30,000$26.28$788,400.00View SEC Filing  
10/1/2014Stephen GarbaczInsiderSell868$27.06$23,488.08View SEC Filing  
9/22/2014Robert A CopelandEVPSell20,000$25.55$511,000.00View SEC Filing  
9/15/2014Eric HedrickInsiderSell2,000$28.67$57,340.00View SEC Filing  
9/4/2014Carl GoldfischerDirectorSell4,000$35.14$140,560.00View SEC Filing  
8/26/2014Bay City Capital LlcMajor ShareholderSell200,000$35.14$7,028,000.00View SEC Filing  
8/25/2014Bay City Capital LlcMajor ShareholderSell366,666$33.98$12,459,310.68View SEC Filing  
8/18/2014Robert A CopelandEVPSell10,830$36.07$390,638.10View SEC Filing  
8/15/2014Ryan D DrantMajor ShareholderSell4,061$36.54$148,388.94View SEC Filing  
8/4/2014Jason P RhodesCFOSell30,000$29.74$892,200.00View SEC Filing  
8/4/2014Robert A CopelandEVPSell20,000$29.42$588,400.00View SEC Filing  
7/15/2014Eric HedrickInsiderSell2,000$31.35$62,700.00View SEC Filing  
7/7/2014Jason P RhodesCFOSell30,000$32.74$982,200.00View SEC Filing  
7/1/2014Robert J GouldCEOSell30,000$31.53$945,900.00View SEC Filing  
6/23/2014Robert A CopelandEVPSell20,000$28.42$568,400.00View SEC Filing  
6/16/2014Eric HedrickInsiderSell2,000$26.42$52,840.00View SEC Filing  
6/16/2014Robert A CopelandEVPSell25,012$26.38$659,816.56View SEC Filing  
6/2/2014Robert J GouldCEOSell30,000$22.20$666,000.00View SEC Filing  
5/19/2014Robert CopelandEVPSell5,000$22.28$111,400.0017,561View SEC Filing  
5/5/2014Jason RhodesCFOSell30,000$21.53$645,900.0046,000View SEC Filing  
5/5/2014Robert CopelandEVPSell10,000$21.29$212,900.0020,011View SEC Filing  
5/1/2014Robert GouldCEOSell30,000$21.91$657,300.00View SEC Filing  
4/28/2014Robert CopelandEVPSell13,800$20.73$286,074.0024,911View SEC Filing  
4/7/2014Jason RhodesCFOSell25,000$20.05$501,250.0034,000View SEC Filing  
4/7/2014Robert GouldCEOSell30,000$20.22$606,600.00View SEC Filing  
2/10/2014Celgene European Investment Comajor shareholderBuy340,000$29.25$9,945,000.00View SEC Filing  
1/6/2014Jason RhodesCFOSell10,000$20.19$201,900.004,000View SEC Filing  
12/16/2013Robert CopelandEVPSell4,600$21.21$97,566.0053,544View SEC Filing  
12/2/2013Robert CopelandEVPSell5,000$20.70$103,500.0053,544View SEC Filing  
11/15/2013M James Barrettmajor shareholderBuy406,500$19.68$7,999,920.00View SEC Filing  
6/5/2013David M MottDirectorBuy400,000$15.00$6,000,000.00View SEC Filing  
6/5/2013Venture Fund I L.P. AstellasMajor ShareholderBuy15,333$15.00$229,995.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Epizyme (NASDAQ EPZM) News Headlines

Source:
DateHeadline
-$0.54 Earnings Per Share Expected for Epizyme (EPZM) This Quarter-$0.54 Earnings Per Share Expected for Epizyme (EPZM) This Quarter
www.americanbankingnews.com - April 22 at 3:08 AM
Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?Why Is Epizyme (EPZM) Down 18% Since Its Last Earnings Report?
www.zacks.com - April 12 at 9:26 AM
Epizymes (EPZM) "Buy" Rating Reiterated at HC WainwrightEpizyme's (EPZM) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - April 12 at 12:29 AM
Epizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock UpEpizyme (EPZM) Publishes Tazemetostat Phase I Data, Stock Up
finance.yahoo.com - April 11 at 5:03 PM
Epizyme (EPZM) Reports Publication of Tazemetostat Phase 1 Clinical Data in The Lancet OncologyEpizyme (EPZM) Reports Publication of Tazemetostat Phase 1 Clinical Data in The Lancet Oncology
www.streetinsider.com - April 10 at 5:05 PM
Epizyme (EPZM) Downgraded to "Hold" at BidaskClubEpizyme (EPZM) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 10 at 10:25 AM
ValuEngine Downgrades Epizyme (EPZM) to Strong SellValuEngine Downgrades Epizyme (EPZM) to Strong Sell
www.americanbankingnews.com - April 10 at 12:32 AM
Epizyme (EPZM) Upgraded by Zacks Investment Research to "Buy"Epizyme (EPZM) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 7 at 9:13 AM
Epizyme (EPZM) Expected to Announce Quarterly Sales of $750,000.00Epizyme (EPZM) Expected to Announce Quarterly Sales of $750,000.00
www.americanbankingnews.com - April 7 at 4:43 AM
BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not DisclosedBRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed
www.reuters.com - April 6 at 9:00 AM
Zacks: Analysts Anticipate Epizyme (EPZM) Will Post Earnings of -$0.54 Per ShareZacks: Analysts Anticipate Epizyme (EPZM) Will Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - April 5 at 5:28 AM
Epizyme (EPZM) Given Average Rating of "Buy" by AnalystsEpizyme (EPZM) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 5 at 3:24 AM
Epizyme (EPZM) Stock Rating Lowered by BidaskClubEpizyme (EPZM) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 3 at 11:02 AM
Epizyme (EPZM) Rating Lowered to Sector Perform at Royal Bank of CanadaEpizyme (EPZM) Rating Lowered to Sector Perform at Royal Bank of Canada
www.americanbankingnews.com - April 2 at 8:40 AM
Epizyme (EPZM) Given Buy Rating at CannEpizyme (EPZM) Given Buy Rating at Cann
www.americanbankingnews.com - April 2 at 8:31 AM
Epizyme (EPZM) Rating Reiterated by HC WainwrightEpizyme (EPZM) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - April 1 at 11:24 PM
Epizyme (EPZM) Rating Lowered to Sell at ValuEngineEpizyme (EPZM) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 1 at 7:35 PM
Edited Transcript of EPZM earnings conference call or presentation 13-Mar-18 12:30pm GMTEdited Transcript of EPZM earnings conference call or presentation 13-Mar-18 12:30pm GMT
finance.yahoo.com - April 1 at 8:49 AM
Zacks Investment Research Lowers Epizyme (EPZM) to SellZacks Investment Research Lowers Epizyme (EPZM) to Sell
www.americanbankingnews.com - March 30 at 10:02 PM
Epizyme (EPZM) Earns Overweight Rating from Analysts at Morgan StanleyEpizyme (EPZM) Earns Overweight Rating from Analysts at Morgan Stanley
www.americanbankingnews.com - March 29 at 3:01 PM
Epizyme (EPZM) Upgraded at BidaskClubEpizyme (EPZM) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 10:59 AM
Epizyme Inc (EPZM) Expected to Post Earnings of -$0.54 Per ShareEpizyme Inc (EPZM) Expected to Post Earnings of -$0.54 Per Share
www.americanbankingnews.com - March 19 at 3:06 AM
Wedbush Weighs in on Epizyme Incs Q1 2018 Earnings (EPZM)Wedbush Weighs in on Epizyme Inc's Q1 2018 Earnings (EPZM)
www.americanbankingnews.com - March 19 at 1:54 AM
Epizyme (EPZM) Rating Increased to Buy at BidaskClubEpizyme (EPZM) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - March 17 at 6:14 PM
Epizyme (EPZM) Downgraded by Zacks Investment Research to HoldEpizyme (EPZM) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 16 at 12:04 PM
Epizyme Inc Forecasted to Earn Q2 2018 Earnings of ($0.59) Per Share (EPZM)Epizyme Inc Forecasted to Earn Q2 2018 Earnings of ($0.59) Per Share (EPZM)
www.americanbankingnews.com - March 16 at 9:06 AM
Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4 - NasdaqEpizyme (EPZM) Reports Narrower-than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 16 at 8:54 AM
Oppenheimer Weighs in on Epizyme Incs Q1 2018 Earnings (EPZM)Oppenheimer Weighs in on Epizyme Inc's Q1 2018 Earnings (EPZM)
www.americanbankingnews.com - March 16 at 8:40 AM
Epizyme Inc to Post Q1 2018 Earnings of ($0.54) Per Share, Leerink Swann Forecasts (EPZM)Epizyme Inc to Post Q1 2018 Earnings of ($0.54) Per Share, Leerink Swann Forecasts (EPZM)
www.americanbankingnews.com - March 16 at 8:37 AM
FY2022 EPS Estimates for Epizyme Inc Reduced by Analyst (EPZM)FY2022 EPS Estimates for Epizyme Inc Reduced by Analyst (EPZM)
www.americanbankingnews.com - March 15 at 3:10 PM
Epizyme (EPZM) Upgraded at Zacks Investment ResearchEpizyme (EPZM) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 15 at 12:51 PM
FY2018 EPS Estimates for Epizyme Inc Decreased by Analyst (EPZM)FY2018 EPS Estimates for Epizyme Inc Decreased by Analyst (EPZM)
www.americanbankingnews.com - March 15 at 9:28 AM
Epizyme (EPZM) Given New $24.00 Price Target at Leerink SwannEpizyme (EPZM) Given New $24.00 Price Target at Leerink Swann
www.americanbankingnews.com - March 14 at 9:02 PM
Wedbush Lowers Epizyme (EPZM) Price Target to $25.00Wedbush Lowers Epizyme (EPZM) Price Target to $25.00
www.americanbankingnews.com - March 14 at 9:02 PM
Epizyme (EPZM) Rating Reiterated by SunTrust BanksEpizyme (EPZM) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - March 14 at 9:02 PM
Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q4
www.msn.com - March 14 at 6:31 PM
Top Analyst Upgrades and Downgrades: Abercrombie, Altria, Century Aluminum, DSW, Ford, Quest Diagnostics, Sunoco and MoreTop Analyst Upgrades and Downgrades: Abercrombie, Altria, Century Aluminum, DSW, Ford, Quest Diagnostics, Sunoco and More
247wallst.com - March 14 at 9:22 AM
Epizyme (EPZM) Releases  Earnings Results, Beats Estimates By $0.06 EPSEpizyme (EPZM) Releases Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - March 13 at 9:36 AM
Epizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 MilestonesEpizyme Reports Fourth Quarter and Full Year 2017 Operating Results and 2018 Milestones
finance.yahoo.com - March 13 at 8:59 AM
Epizyme, Inc. to Host Earnings CallEpizyme, Inc. to Host Earnings Call
finance.yahoo.com - March 13 at 8:59 AM
Epizyme (EPZM) Reports Narrower-than-Expected Q4 LossEpizyme (EPZM) Reports Narrower-than-Expected Q4 Loss
finance.yahoo.com - March 13 at 8:58 AM
Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of DirectorsEpizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors
finance.yahoo.com - March 12 at 6:09 PM
Epizyme Inc (EPZM) Receives Consensus Rating of "Buy" from AnalystsEpizyme Inc (EPZM) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 11 at 4:28 AM
Should You Buy Epizyme (EPZM) Ahead of Earnings? - NasdaqShould You Buy Epizyme (EPZM) Ahead of Earnings? - Nasdaq
www.nasdaq.com - March 9 at 6:13 PM
Should You Buy Epizyme (EPZM) Ahead of Earnings?Should You Buy Epizyme (EPZM) Ahead of Earnings?
www.zacks.com - March 9 at 9:04 AM
Epizyme (EPZM) and Insmed (INSM) Head-To-Head ComparisonEpizyme (EPZM) and Insmed (INSM) Head-To-Head Comparison
www.americanbankingnews.com - March 8 at 5:11 PM
Epizyme (EPZM) Downgraded by ValuEngine to SellEpizyme (EPZM) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 4 at 7:16 PM
Epizyme (EPZM) Upgraded by BidaskClub to "Buy"Epizyme (EPZM) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - March 3 at 12:00 PM
Hudson Bay Capital Management LP Takes $1.57 Million Position in Epizyme Inc (EPZM)Hudson Bay Capital Management LP Takes $1.57 Million Position in Epizyme Inc (EPZM)
www.americanbankingnews.com - March 2 at 12:57 PM
Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation ... - GlobeNewswire (press release)Epizyme Announces Date of Fourth Quarter and Full Year 2017 Results Conference Call and Upcoming Presentation ... - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:39 AM

SEC Filings

Epizyme (NASDAQ:EPZM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Epizyme (NASDAQ:EPZM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Epizyme (NASDAQ EPZM) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.